$5 And Under
FONT-SIZE Plus   Neg

Amicus Therapeutics Inc. (FOLD) Is Sinking On Phase 3 Study Results

Amicus Therapeutics Inc. (FOLD: Quote) and GlaxoSmithKline (GSK: Quote) announced the 6-month primary treatment period results from the first Phase 3 study of oral migalastat HCl monotherapy in males and females with Fabry disease. The study did not achieve statistical significance according to the pre-specified primary endpoint analysis.

Amicus Therapeutics traded in a narrow range throughout Wednesday's session and finished up by 0.11 at $5.77. The stock is now down 2.80 on 637K shares after the bell.

Click here to receive FREE breaking news email alerts for Amicus Therapeutics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus